About Intercell
Intercell is a company based in Vienna (Austria) founded in 1998 by Arunabh Varma. Intercell has raised $78.62 million across 2 funding rounds from investors including Global Life Science Ventures. Intercell has completed 1 acquisition, including Iomai Corporation. Intercell operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Vienna, Austria
- Founders Arunabh Varma
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$78.62 M (USD)
in 2 rounds
-
Latest Funding Round
$44.98 M (USD), Series B
Feb 23, 2011
-
Investors
Global Life Science Ventures
& 1 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
N/A
(Dec 17, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Intercell
Intercell has successfully raised a total of $78.62M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $44.98 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intercell
Intercell has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Global Life Science Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early & late stage life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked |
Investor details for Intercell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intercell
Intercell has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Iomai Corporation.
Investment portfolio details for Intercell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vaccines and immune stimulants are developed via needle-free transcutaneous immunization.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Intercell
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Intercell
Detailed financials for Intercell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intercell Comparisons
Peer comparison for Intercell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intercell
Intercell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
Developer of computationally designed VLP vaccines for treating multiple infections
|
Detailed competitors of Intercell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intercell
Complete news archive for Intercell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intercell
Intercell was founded in 1998 and raised its 1st funding round 5 years after it was founded.
Intercell is headquartered in Vienna, Austria.
Arunabh Varma is the current CEO of Intercell. They have also founded this company.
Intercell is a funded company, having raised a total of $78.62M across 2 funding rounds to date.
Founded in 1998 in Vienna, Austria, Intercell focused on biotechnology within the infectious disease sector. Vaccines, antigens, and adjuvants were developed for various applications, with a Japanese encephalitis vaccine already marketed. Operations centered on research and production until the 2012 acquisition by Vivalis for 174 million, after which the combined entity was renamed Valneva.
Intercell's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Intercell has made 1 acquisition, including Iomai Corporation.
Intercell has 1 investor. Key investors include Global Life Science Ventures.